What the FDA labels say about taking them together
Atazanavir and mometasone
Mometasone's FDA label of August 19, 2026 names atazanavir in its drug interactions (prescription label) section; atazanavir's label does not name mometasone itself but warns about its class (Corticosteroids). The mometasone label: “Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the coadministration of ASMANEX HFA with ketoconazole, and other known strong cytochrome P450 (CYP) isoenzyme 3A4 …”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the mometasone FDA label on DailyMed (effective August 19, 2026, L. Perrigo Company).
What does the atazanavir label say about mometasone?
Atazanavir's label does not name mometasone itself; it warns about its class (Corticosteroids):
Atazanavir label, drug interactionsCorticosteroids: dexamethasone and other corticosteroids (all routes of administration) ↓ atazanavir ↑ corticosteroids Coadministration with dexamethasone or other corticosteroids that induce CYP3A may result in loss of therapeutic effect of atazanavir and development of resistance to atazanavir and/or ritonavir.
Atazanavir label, drug interactionsCoadministration with corticosteroids (all routes of administration) that are metabolized by CYP3A, particularly for long-term use, may increase the risk for development of systemic corticosteroid effects including Cushing’s syndrome and adrenal suppression.
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the mometasone label say about atazanavir?
Mometasone label, drug interactions (prescription label)Caution should be exercised when considering the coadministration of mometasone furoate monohydrate nasal spray with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, cobicistat-containing products, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Clinical Pharmacology (12.3) ].
Asmanex Hfa label (Organon LLC, July 7, 2026), warnings and precautionsInteractions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the coadministration of ASMANEX HFA with ketoconazole, and other known strong cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4) inhibitors (e.g., ritonavir, cobicistat-containing products, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to increased systemic exposure to mometasone furoate may occur [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ].
Source: FDA drug label (Asmanex Hfa, NDA205641), Organon LLC, effective July 7, 2026 (SPL set 0c6d63da-41bc-4894-bead-198e66c848ac), via openFDA
Source: FDA drug label (Asmanex, NDA021067), Organon LLC, effective July 7, 2026 (SPL set 10b36fb2-6b0d-4f20-b197-3564d6f594b9), via openFDA
Source: FDA drug label (Nasonex), L. Perrigo Company, effective August 19, 2026 (SPL set 13696a8b-366a-4a5e-adea-d5b7bff9e46f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Mometasone | |
|---|---|---|
| Labeled for | HIV | Allergies, Asthma |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | $0.354 per gram 0.1% cream |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once